• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Editor's Pick Hims & Hers Health says it will offer compounded GLP-1 injections
Editor's Pick

Hims & Hers Health says it will offer compounded GLP-1 injections

by May 22, 2024
by May 22, 2024 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday.

Shares of the company surged.

The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — such as Ozempic and Wegovy, which have skyrocketed in popularity — were not previously offered as part of that program.

Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform. Hims & Hers said it plans to make branded GLP-1 medications available to its customers once supply is consistently available.

The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Even before it added compounded GLP-1s to its portfolio, Hims & Hers said in its fourth-quarter earnings report that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The company plans to offer updated guidance in its next earnings report.

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage.

GLP-1s mimic a hormone produced in the gut to tamp down a person’s appetite and regulate their blood sugar. When those medications are in shortage, certain manufacturers can prepare a compounded version if they meet U.S. Food and Drug Administration requirements.

The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient’s needs.

In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.

Hims & Hers CEO Andrew Dudum told CNBC that the company is “confident” that customers will be able to access a consistent supply of the compounded medications.

Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and has partnered with one of the largest generic manufacturers in the country that has FDA oversight.

“We have a certain degree of exclusivity with that facility that will guarantee our consumers consistent volume and supply,” he said.

This post appeared first on NBC NEWS
You Might Also Like
  • SEC charges Carl Icahn with hiding billions of dollars worth of stock pledges
  • Workers wrested a seat at the table on AI this year. Will it be enough?
  • The uncommon lending practices behind Silicon Valley Bank’s woes
  • Walmart, Chipotle and others feel the heat over prices
Share
0
FacebookTwitterPinterestWhatsapp

previous post
US dental care crisis: It should not be a luxury to keep your teeth in your mouth
next post
Nestle to launch frozen pizzas, other foods targeting users of weight-loss drugs

You may also like

The 30-year mortgage rate hits 7.48%, the highest level since...

August 22, 2023

Target unveils new items costing $10 or less — and...

February 19, 2024

College seniors are graduating into a job market in flux,...

May 6, 2023

Intel shares plunge 28%, dragging down global chip stocks

August 2, 2024

Home prices hit record high in June on S&P Case-Shiller...

August 28, 2024

Housing, inflation, interest rates and more: What to expect in...

December 27, 2023

Trump commutes sentence of Ozy Media founder Carlos Watson

March 29, 2025

OpenAI in talks to pay about $3 billion to acquire...

April 17, 2025

Uber delivery chief Gore-Coty is leaving after almost 13 years...

June 3, 2025

Applebee’s owner plots turnaround to lure back fast-food customers and...

May 10, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Week Ahead: As NIFTY Breaks Out, Change Of Leadership Likely To Keep The Index Moving

      June 28, 2025
    • 3 Stock Setups for the Second Half of 2025

      June 28, 2025
    • Fibonacci Retracements: The Key to Identifying True Breakouts

      June 27, 2025
    • All-Time Highs and An Upcoming Rate Cut: We’re Just Getting Started on This Move Higher

      June 27, 2025
    • How to Improve your Trading Odds and Increase Opportunities

      June 27, 2025

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 3,615 views
    • 2

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,895 views
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,588 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,551 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,429 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,151)
    • Investing (538)
    • Stock (2,640)

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 2

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Week Ahead: As NIFTY Breaks Out, Change Of Leadership Likely...

      June 28, 2025
    • 3 Stock Setups for the Second Half of 2025

      June 28, 2025
    • Fibonacci Retracements: The Key to Identifying True Breakouts

      June 27, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,151)
    • Investing (538)
    • Stock (2,640)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    Paramount ends DEI policies, cites Trump...

    February 28, 2025

    U.S. charges former Wamco executive Kenneth...

    November 26, 2024

    Amazon surpasses Walmart in revenue for...

    February 21, 2025
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here